.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR08_EmtricitabineTenofovirDisoproxil.EmtricitabineTenofovirDisoproxil .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR08_EmtricitabineTenofovirDisoproxil.EmtricitabineTenofovirDisoproxil| name: | EmtricitabineTenofovirDisoproxilAndRilpivirine |
| ATC code: | J05AR08 | route: | oral |
| n-compartments | 1 |
A fixed-dose combination antiretroviral medication containing the nucleoside reverse transcriptase inhibitor (NRTI) emtricitabine, the nucleotide reverse transcriptase inhibitor (NtRTI) tenofovir disoproxil, and the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine. It is approved and used in the treatment of HIV-1 infection in adults and some adolescents.
Pharmacokinetic parameters summarized from published studies in healthy HIV-negative and HIV-infected adult subjects receiving the fixed-dose combination orally under fed conditions (emtricitabine 200 mg, tenofovir disoproxil fumarate 245 mg, rilpivirine 25 mg, once daily).
Ogbuagu, O (2016). Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients. Expert review of anti-infective therapy 14(12) 1113–1126. DOI:10.1080/14787210.2016.1255551 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27797606
Néant, N, et al., & Solas, C (2018). Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine. European journal of clinical pharmacology 74(4) 473–481. DOI:10.1007/s00228-017-2405-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29374296